Syncona Ltd on Friday reported promising trial results for the drug laru-zova, the lead asset of Syncona subsidiary B ...
Subscribe now to see this Premium News article from
Alliance News Professional covers every UK stock in your portfolio. It goes beyond regulatory news and free web services to give your investment decisions an edge over the crowd.
Click for a FREE Trial
  • In The Know - Management and analyst comments that go beyond company announcements.
  • Flash headlines on all 2,400 London-listed companies before the news hits the open web.
  • Broker Ratings - The earliest tip-offs, many before the market opens.
  • Economic data and central bank flashes from UK, US and eurozone.
  • Taking AIM - Up to the minute market commentary on AIM stocks.
  • Over 500 news items per trading day for just £39.60 per month, and cancel at any time.
Try Alliance News FREE for 1 Month
Call us on +44 (0) 203 8794 460 to get started.
Syncona (LSE:SYNC)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Syncona.
Syncona (LSE:SYNC)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Syncona.